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Abstract
Objectives: To evaluate the risk of having a stroke and the risk of bleeding in institutionalized patients with atrial
fibrillation. Atrial fibrillation is a common cardiac arrhythmia associated with increased morbidity and mortality. It is
necessary to develop pharmacotherapy plans to minimize the risk.
Design: A prospective study.
Setting: Institutionalized patients.
Participants: Inclusion criteria were: patients diagnosed with atrial fibrillation, with or without treatment for the
prevention of stroke.
Main outcome measures: The evaluation of the CHA2DS2-VASc criteria was performed. The risk of hemorrhage
was assessed using the HAS-BLED scale, based on the risk factors associated with the probability of bleeding.
Results:We included 53 patients (86.4  6.4 years, 30.2% men). Of these, 37 (69.8%) were correctly anticoagulated. Of
the remaining, 5 patients (31.2%) did not have any type of anticoagulant or antiaggregant treatment and 11 (68.7%) were
treated with antiaggregant alone. The pharmaceutical intervention was performed in patients who did not meet stroke
criteria. Of the untreated patients: two died before the intervention, two were recommended to be referred to
cardiology and in one there was no intervention because of very advanced age. In the antiaggregant patients, it was
decided not to modify the treatment. The reasons were: high risk of bleeding, very advanced age, advanced dementia or
terminal illness, moderate risk of stroke, and clotting factor deficiency.
Conclusions: The risk of stroke in elderly patients with atrial fibrillation is high, so it is important to control the
risk factors.
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Introduction
Atrial fibrillation (AF) it is the most frequent arrhyth-
mia in the population and its prevalence increases with
age. It has a high morbidity due to both the direct
symptoms and its side effects. Among them, it is
worth mentioning that it is an important risk factor
for the development of stroke due to thromboembolism
(TE). Non-valvular AF increases the risk of stroke by
5, but valvular AF does so by 20. More than three
million people in the world suffer a stroke related to
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AF each year.1 The risk of stroke is similar for any type
of AF (paroxysmal, persistent, or permanent) and for
flutter, and in any of them, advanced age is the main
risk factor. Seventy-five percent of anterior circulation
strokes in patients with AF are cardioembolic.2
The prevention of thromboembolic complications is
one of the main objectives of the therapeutic strategy of
AF, specifically the reduction of thromboembolic risk
with the use of antithrombotic treatment based on a
specific risk/benefit assessment for each patient. The
risk factors for stroke and/or systemic embolism in
patients with AF are as follows: history of cerebrovas-
cular accident (CVA), advanced age, diabetes mellitus
(DM), arterial hypertension, coronary artery disease,
and congestive heart failure (CHF). All patients with
AF who present any of these associated risk factors
should be treated with antithrombotic medication indi-
vidualized in each particular case, according to the risk/
benefit ratio.
Several instruments have been developed to define
the stroke risk of each patient with AF. The recom-
mended one at present is the CHF, hypertension, age
> 75, diabetes, prior stroke/transient ischemic attack-
vascular disease, age 65–74 years, sex category
(CHA2DS2-VASc),3 that improves the risk definition
of its predecessor, chronic heart failure, hypertension,
advanced age, diabetes, and prior stroke/transient
ischemic attack, which presented limitations, such as
a large percentage of patients classified as intermediate
risk and the lack of some risk factors such as sex and
peripheral vascular disease.This scale is used to deter-
mine whether or not the patient requires anticoagulant
or antiaggregant treatment. The risk factors are cumu-
lative, and the simultaneous presence of two or more
“clinically relevant, not major” risk factors would jus-
tify a stroke risk high enough to require
anticoagulation.
The wide use of oral anticoagulant in patients with
AF, and the risk of bleeding that is implicit, has forced
to develop several instruments to predict the risk of
bleeding during the first year of anticoagulation. The
most used is hypertension, abnormal renal/liver func-
tion, stroke, bleeding history or predisposition, labile
international normalized ratio (INR), elderly (>65),
drugs/alcohol concomitantly (HAS-BLED).4This scale
allows calculating the risk of bleeding in patients with
AF, based on the risk factors associated with the prob-
ability of bleeding, and has demonstrated its usefulness
in defining high-risk patients, identifying the factors
that should be optimized for anticoagulation safe and
help in the decision-making process of antithrom-
botic treatment.
During the last decades, several antithrombotic
modalities have been evaluated in this clinical situation:
the vitamin K antagonists in adjusted dose, the factor
II inhibitor (dabigatran), the factor Xa inhibitors
(rivaroxaban, apixaban, and edoxaban).1
Acetylsalicylic acid and clopidogrel, as antiplatelet
agents, are also frequently used alternatives in the
elderly.5 It is necessary to develop quality pharmaco-
therapy and minimize the intrinsic risk associated with
the use of medications.6
The aim of this study is to evaluate the risk of pre-
senting a stroke and the risk of bleeding in institution-
alized patients in dependent elderly residences
diagnosed with cardiac arrhythmia due to atrial fibril-
lation (CAAF).
Material and methods
Prospective study conducted between February 2018
and April 2018 in a total of 414 patients institutional-
ized in three RPMD dependent on the same Hospital
Pharmacy Service located in a social health center. The
inclusion criteria used were: all patients diagnosed with
CAAF, with or without treatment for the prevention of
stroke. By reviewing medical records and consulting
the pharmacotherapy computer program, the demo-
graphic and clinical variables necessary for the study
were collected. The selected patients underwent evalu-
ation of the CHA2DS2-VASc criteria,7 scoring the fol-
lowing variables: heart failure, hypertension, age (>75),
DM, previous stroke, vascular disease, and female sex.
The result of 1 to 9 points determines the type of risk
and percentage of risk of presenting a stroke per year.
It is used to determine whether or not the patient
requires anticoagulant or antiaggregant treatment.
In the same way, the risk of hemorrhage of these
patients was evaluated through the hypertension,
abnormal renal and liver function, stroke, bleeding,
labile INR, elderly drugs or alcohol (HAS-BLED)
scale, based on the risk factors associated with the
probability of bleeding: hypertension, renal and hepatic
function, previous stroke, history of bleeding, INR
labile, age (>65), drugs, and alcohol.
The results determine the type of risk of bleeding
and recommendations, as indicated in Table 1. A
score of 3 or more points indicates a higher risk of
bleeding in one year with the correct anticoagulation
and justifies surveillance or a review of the patient,
more regularly. The risk is based on the possibility of
developing a hemorrhagic process (intracranial hemor-
rhage, hemorrhage requiring hospitalization or requir-
ing transfusion) or a fall in hemoglobin > 2 g/l.8
Results
A total of 53 patients with a mean age of 86.4  6.4
years were included, of which 30.2% were men, who
underwent both evaluations: CHA2DS2-VASc and
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HAS-BLED; 49.1%, 64.1%, and 33.9% of patients
suffered from chronic diseases such as chronic heart
failure, high blood pressure (HBP) and DM, respective-
ly; 24.5% had history of stroke or TE and 32.1% had
acute myocardial infarction; 20.7% suffered from renal
failure and 5.6% from liver failure; 8.7% had a history
of bleeding, 20.7% unstable or high INR and 79.2%
took other drugs that could predispose to bleeding.
An average CHA2DS2-VASc score of 5.8  1.4 was
obtained, with an average risk of presenting a stroke
per year of 7.4  2.7%.
One hundred percent of the patients obtained values
of risk of stroke between moderate and high, and there-
fore all should take a prophylactic treatment with anti-
coagulants, according to the classification of
CHA2DS2-VASc used. When carrying out the HAS-
BLED analysis, it was found that 26.4% of the patients
suffered an intermediate risk of bleeding and 73.6% a
high risk of suffering some type of hemorrhage.
The analysis indicated that 69.8% (n ¼ 37) of the
patients received anticoagulant treatment, that is, they
complied with the recommendation. Of these, 75.7%
took conventional anticoagulation as acenocoumarol
or warfarin, 18.9% took new anticoagulants (apixaban
and rivaroxaban), and 5.4% were anticoagulated with
chronic low-molecular weight heparins.
The remaining 30.2% (n ¼ 16) of the patients did
not take the recommended anticoagulant treatment
according to the CHA2DS2-VASc scale. Of these,
68.7% (n ¼ 11) were treated with antiaggregants
(Acetylsalicylic acid or clopidogrel) and 31.3% (n ¼
5) did not take any type of treatment.
In all, 68.7% of patients who did not comply with
the recommendations had a risk of 4 of suffering a
cardiovascular event.
Of the untreated patients, 33.3% had a high risk of
hemorrhage according to the HAS-BLED criteria,
while in those treated with antiplatelet drugs it was
72 (7%).
The pharmaceutical intervention was carried out in
patients who did not have any treatment for the pre-
vention of stroke. Of these, 40% (n ¼ 2) died before the
intervention, for reasons other than the study, in 40%
(n ¼ 2) the initiation of antiaggregant treatment was
evaluated for advanced age and high risk of bleeding.
In the remaining 20% (n ¼ 1), after consultation with
the prescribing physician, it was considered appropri-
ate not to perform any type of intervention (patient of
99 years).
In the patients treated with antiaggregants after
review and consultation with the reference physicians,
it was decided not to modify the treatment. The main
reasons for nonintervention were: high risk of bleeding
(27.3%), very advanced age (18.1%), advanced demen-
tia (27.3%), terminal illness (9.1%), moderate risk of
stroke (9.1%), and deficit of coagulation fac-
tors (9.1%).
Discussion
In the present study, the biometric characteristics and
health status of 53 institutionalized patients diagnosed
with CAAF and the need for anticoagulant treatment
according to the risk of suffering a CVA as well as the
risk of hemorrhage have been evaluated.
Pharmaceutical intervention in those patients who did
not comply with the recommendations.9 With this, we
wanted to demonstrate a part of the great field that
encompasses pharmacotherapeutic surveillance in this
type of elderly patients – chronic – polymedicated. The
importance of pharmacotherapy follow-up in institu-
tionalized patients is essential to avoid an increase in
morbidity and mortality.
The work carried out has a series of limitations: the
sample is limited; conditioned directly by the popula-
tion of institutionalized elderly patients with CAAF
that exists in the geographical area of study. In addi-
tion, since it is a retrospective study, there may be loss
of information in the variables collected from the clin-
ical history. Finally, these are elderly patients with
many comorbidities and polymedicates, so it is not
always possible to follow the anticoagulation recom-
mendations as they are described in the literature.6
In this study, it has been shown that the care of the
institutionalized elderly patient should not be directed
to treat each of the diseases in isolation, but should
consider the multi-pathological nature, the presence
of geriatric syndromes intimately related to their qual-
ity of life, and the needs and expectations of the
patient. Furthermore, in this type of patients it is not
always possible or convenient to adapt exclusively to
what the guidelines recommend, the treatment must be
individualized according to the situation, with patient
safety always being a priority. Therefore, it is necessary
to develop quality pharmacotherapy and minimize the
intrinsic risk associated with the use of medications.
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